Molecularly imprinted polymers for the determination of a pharmaceutical development compound in plasma using 96-well MISPE technology.
The use of molecularly imprinted polymers (MIPs) as sorbents for the solid phase extraction (SPE) of a pharmaceutical compound in development, prior to quantitative analysis was investigated. Three MIPs were synthesised using a structural analogue as the template molecule. Each polymer was prepared with different monomers and porogens. The MIPs were then tested for their performance both in organic and aqueous environments, the final aim being to load plasma directly onto the polymers. At an early development stage, there is a limited amount of compound available. Due to this limitation, reducing the amount of template required for imprinting was investigated. A MIP capable of extracting the analyte directly from plasma was produced. The specificity of the polymer allowed the method to be validated at a lower sensitivity than a more conventional SPE assay. For the first time, MIPs were packed into 96-well blocks enabling high throughput analysis. The analytical method was fully validated for imprecision and inaccuracy down to 4 ng/ml in plasma.
Chassaing
C
C
Christophe Chassaing, Bioanalytical Group, Drug Metabolism, IPC 664, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK. christophe_chassaing@sandwich.pfizer.com
Stokes
J
J
Venn
R F
RF
Lanza
F
F
Sellergren
B
B
Holmberg
A
A
Berggren
C
C
D015195:Drug Design; D004364:Pharmaceutical Preparations / Q000097:blood*; D011108:Polymers / Q000737:chemistry*; D012015:Reference Standards; D015203:Reproducibility of Results
D004364:Pharmaceutical Preparations; D011108:Polymers